1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Diamyd Medical Gets Second FDA’s FTA for Diamyd

22 Jul 2024
Admin
News Article

Diamyd Medical Gets Second FDA’s FTA for Diamyd

Diamyd Medical gets second US FDA Fast Track designation for Diamyd for prevention of type 1 diabetes

Overview

Diamyd Medical, develops precision medicine therapies for the prevention and treatment of autoimmune diabetes, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd (rhGAD65/alum) to treat type 1 diabetes in paediatric patients with stage 1 or stage 2 type 1 diabetes carrying the genotype HLA DR3-DQ2.

Diamyd’s FTA

Earlier this year, Diamyd received Fast Track designation for the treatment of individuals with stage 3 type 1 diabetes carrying the HLA DR3-DQ2 genotype.
The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.
Fast Track designation is intended to bring promising medicines to patients sooner.

Words from CEO: Diamyd Medical

“We are thrilled to receive our second Fast Track designation for Diamyd, this time for its potential to delay the onset of clinically diagnosed type 1 diabetes"", says Ulf Hannelius, CEO of Diamyd Medical.
“This recognition once again underscores the potential of our precision medicine approach and the urgent need for new treatment options for type 1 diabetes across the disease spectrum. We now have the opportunity to work closely with the FDA to accelerate the development of Diamyd also as a preventive medicine.”

About Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic autoimmune disease that attacks the insulin producing beta cells in the pancreas.
The onset of T1D starts months to years before symptomatic disease and is divided into disease stages.
Individuals with stage 1 T1D have tested positive for two or more diabetes-related autoantibodies but still have normal blood glucose values and no symptoms of the disease.
Individuals with stage 2 T1D have progressed to abnormal blood glucose values (so-called dysglycemia) but are otherwise asymptomatic.
Stage 3 T1D is synonymous with clinically diagnosed type 1 diabetes.

About Diamyd Medical

Diamyd Medical develops treatments for all stages of T1D. The target population for the DiaPrecise trial comprises individuals with stages 1 T1D or stage 2 T1D, whilst individuals with stage 3 T1D (i.e. clinically diagnosed T1D) are the target population for the pivotal phase III trial DIAGNODE-3 with the antigen-specific immunotherapy Diamyd.